Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

1. In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy.Endocrine · 2025
   Article
2. Effects of linsitinib on M22 and IGF:1-treated 3D spheroids of human orbital fibroblasts.Scientific reports · 2025
   Article
3. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.The Journal of clinical endocrinology and metabolism · 2022
   Article
4. Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormone Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases - Why Not This One?Frontiers in immunology · 2022
   Article
5. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.Journal of endocrinological investigation · 2020
   Article
6. Modulating TSH Receptor Signaling for Therapeutic Benefit.European thyroid journal · 2020
   Article
7. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.Journal of endocrinological investigation · 2019
   Article
8. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.Endocrine reviews · 2019
   Review
9. Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors.Thyroid : official journal of the American Thyroid Association · 2018
   Article
10. Rebuttal to Smith and Janssen (Thyroid 2017;27:746-747. DOI: 10.1089/thy.2017.0281).Thyroid : official journal of the American Thyroid Association · 2017
    Article

Corrections and comments

• Commented on by
  Rebuttal to Smith and Janssen (Thyroid 2017;27:746-747. DOI: 10.1089/thy.2017.0281).2017
• Comment on
  Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.2016
• Comment on
  TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.2017

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

Abstract

PubMed holds no abstract for this paper.